EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Kontinuierliche Glukosemesssysteme bei Menschen mit Typ-2-Diabetes ohne Insulintherapie: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien

Rafael Oliva Morgado Ferreira iD, Talita Trevisan, Eric Pasqualotto iD, Matheus Pedrotti Chavez iD, Beatriz Friedrichsen Marques iD, Rodrigo Nunes Lamounier, Simone van de Sande-Lee iD

Diabetes Technology & Therapeutics · 2024-04 · 26 (4) · 252-262

DOI: 10.1089/dia.2023.0390 ↗

Auf einen Blick

Sechs RCTs mit 407 Menschen mit Typ-2-Diabetes ohne Insulintherapie zeigen unter CGM bessere glykämische Werte als unter SMBG.

Fragestellung

Verbessert CGM im Vergleich zu SMBG die Glukosekontrolle bei Menschen mit Typ-2-Diabetes ohne Insulintherapie?

Methode

Systematische Übersicht und Metaanalyse von RCTs; Suche in PubMed, Cochrane und Embase; Vergleich CGM vs. SMBG.

Ergebnisse

6 RCTs mit 407 Teilnehmenden. HbA1c: WMD −0,31 % (95 %-KI −0,42 bis −0,21; I²=0 %); Glukose: WMD −11,16 mg/dL (95 %-KI −19,94 bis −2,39); Zeit im Zielbereich: WMD 8,63 % (95 %-KI 4,54–12,71).

Schlussfolgerung der Autor:innen

rt-CGM und is-CGM waren im Vergleich zu SMBG mit einer Verbesserung der glykämischen Kontrolle bei Menschen mit T2D ohne Insulintherapie verbunden.

Kernaussagen

  • HbA1c unter CGM geringer als unter SMBG
  • Zeit im Zielbereich und Zufriedenheit höher
  • 6 RCTs mit 407 Teilnehmenden

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 28.03.2024. Verfasst von Rafael Oliva Morgado Ferreira und 6 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Santa Catarina, Department of Internal Medicine, Florianopolis, Brazil. Hauptthemen laut MEDLINE: Blood Glucose, Continuous Glucose Monitoring, Diabetes Mellitus, Type 2, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 37 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Continuous glucose monitoring (CGM) has shown favorable outcomes in patients with type 2 diabetes (T2D) who are on insulin therapy. However, the efficacy of CGM in managing glucose levels in noninsulin-treated people with T2D remains controversial.

Methods

PubMed, Cochrane, and Embase were searched for randomized controlled trials (RCTs) comparing CGM to self-monitoring of blood glucose (SMBG) in people with T2D not using insulin. We computed weighted mean differences (WMDs) and standard mean differences (SMD) for continuous outcomes, with 95% confidence intervals (CIs). Heterogeneity was assessed using I 2 statistics. Statistical analyses were performed using R version 4.2.3.

Results

We included six RCTs comprising 407 noninsulin-treated people with T2D of whom 228 were randomized to CGM. Diabetes duration ranged from 5.4 to 13.9 years. The mean age was 57.9 years and the mean body mass index was 30.8 kg/m 2 . Four trials used real-time CGM (rt-CGM) and two intermittent scanning CGM (is-CGM). Compared with SMBG, CGM significantly reduced the glycated hemoglobin level (WMD −0.31%; 95% CI −0.42 to −0.21; I 2 = 0%), glucose level (WMD −11.16 mg/dL; 95% CI −19.94 to −2.39; I 2 = 0%), time in hypoglycemia level 2 (WMD −0.28%; 95% CI −0.52 to −0.03; I 2 = 91%), glucose time >180 mg/dL (WMD −7.75%; 95% CI −12.04 to −3.45; I 2 = 0%), and the standard deviation of glucose variation (WMD −4.00 mg/dL; 95% CI −6.86 to −1.14; I 2 = 0%). CGM also increased time in range (WMD 8.63%; 95% CI 4.54–12.71; I 2 = 0%) and treatment satisfaction (SMD 0.79; 95% CI 0.54–1.05; I 2 = 0%).

Conclusion

In this meta-analysis, rt-CGM and is-CGM were associated with improvement in glycemic control in people with T2D not using insulin when compared to SMBG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseContinuous Glucose MonitoringDiabetes Mellitus, Type 2Randomized Controlled Trials as TopicHumansBlood Glucose Self-MonitoringGlycated HemoglobinHypoglycemic Agents

Stichwörter der Autor:innen

Continuous glucose monitoringGlucose variabilityMeta-analysesSelf-monitoring of blood glucoseType 2 diabetes

Substanzen

Blood GlucoseGlycated HemoglobinHypoglycemic Agents

Autor:innen und Institutionen

  • Federal University of Santa Catarina, Department of Internal Medicine, Florianopolis, Brazil.
  • Private Practice, Talita Trevisan Endocrinologia, Itajaí, Brazil.
  • Department of Internal Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.

ORCID-Profile: Rafael Oliva Morgado Ferreira, Eric Pasqualotto, Matheus Pedrotti Chavez, Beatriz Friedrichsen Marques, Simone van de Sande-Lee

Zitieren

APA

Ferreira, R. O. M., Trevisan, T., Pasqualotto, E., Chavez, M. P., Marques, B. F., Lamounier, R. N., & van de Sande-Lee, S. (2024). Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Technology & Therapeutics, 26(4), 252-262. https://doi.org/10.1089/dia.2023.0390

Vancouver

Ferreira ROM, Trevisan T, Pasqualotto E, Chavez MP, Marques BF, Lamounier RN, et al. Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Technology & Therapeutics. 2024;26(4):252-262. doi:10.1089/dia.2023.0390

BibTeX
@article{Ferreira2024,
  author = {Ferreira, Rafael Oliva Morgado and Trevisan, Talita and Pasqualotto, Eric and Chavez, Matheus Pedrotti and Marques, Beatriz Friedrichsen and Lamounier, Rodrigo Nunes and van de Sande-Lee, Simone},
  title = {Continuous Glucose Monitoring Systems in Noninsulin-Treated People with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Diabetes Technology & Therapeutics},
  year = {2024},
  volume = {26},
  number = {4},
  pages = {252--262},
  doi = {10.1089/dia.2023.0390}
}
Kostenlos starten →